Lake Street Capital Cuts Stereotaxis (NYSEAMERICAN:STXS) Price Target to $4.00

Stereotaxis (NYSEAMERICAN:STXS – Get Rating) had its price target lowered by Lake Street Capital from $5.00 to $4.00 in a research report released on Monday, The Fly reports. Lake Street Capital currently has a buy rating on the stock.

A number of other equities research analysts also recently commented on the company. B. Riley reduced their target price on Stereotaxis from $6.00 to $5.50 and set a buy rating for the company in a report on Monday. Cowen lowered their target price on shares of Stereotaxis from $7.00 to $5.00 and set an outperform rating on the stock in a research report on Friday, November 11th. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock has an average rating of Buy and a consensus price target of $5.10.

Stereotaxis Stock Down 4.9 %

Shares of STXS opened at $2.32 on Monday. Stereotaxis has a twelve month low of $1.55 and a twelve month high of $3.98.

Hedge Funds Weigh In On Stereotaxis

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Jane Street Group LLC purchased a new position in shares of Stereotaxis during the 4th quarter worth approximately $26,000. Marshall Wace LLP purchased a new position in Stereotaxis during the fourth quarter worth $36,000. Everett Harris & Co. CA raised its holdings in shares of Stereotaxis by 66.7% in the third quarter. Everett Harris & Co. CA now owns 25,000 shares of the company’s stock worth $45,000 after acquiring an additional 10,000 shares during the last quarter. Virtu Financial LLC purchased a new stake in shares of Stereotaxis in the fourth quarter valued at $59,000. Finally, Price T Rowe Associates Inc. MD boosted its stake in shares of Stereotaxis by 88.8% during the third quarter. Price T Rowe Associates Inc. MD now owns 33,600 shares of the company’s stock valued at $61,000 after acquiring an additional 15,800 shares during the last quarter. Institutional investors and hedge funds own 48.13% of the company’s stock.

Stereotaxis Company Profile

(Get Rating)

Stereotaxis, Inc designs, manufactures and markets robotic magnetic navigation systems for use in a hospital’s interventional surgical suite to enhance the treatment of arrhythmias and coronary artery disease. Its products include the Genesis RMN System, the Odyssey Solution, and related devices. The firm also offers the Stereotaxis Imaging Model S x-ray System.